↓ Skip to main content

Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment

Overview of attention for article published in Journal of Translational Medicine, January 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment
Published in
Journal of Translational Medicine, January 2014
DOI 10.1186/1479-5876-12-21
Pubmed ID
Authors

Cristina Stasi, Elisa Triboli, Umberto Arena, Teresa Urraro, Antonio Petrarca, Laura Gragnani, Giacomo Laffi, Anna Linda Zignego

Abstract

Mixed cryoglobulinemia (MC) is a HCV-related lymphoproliferative disorder generally associated with advanced liver disease. Liver stiffness has been significantly correlated with histopathological stage of fibrosis. Moreover, it was influenced by necroinflammatory activity. Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody inducing transient B lymphocytes depletion that was shown to be useful and safe in the majority of HCV MC patients, leading also to improvement of cirrhotic syndrome. Aim of this study was to evaluate the modifications of liver stiffness following RTX treatment in HCV-related MC patients.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 3%
Italy 1 3%
Canada 1 3%
Unknown 27 90%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 20%
Student > Bachelor 5 17%
Student > Master 4 13%
Student > Ph. D. Student 4 13%
Other 2 7%
Other 4 13%
Unknown 5 17%
Readers by discipline Count As %
Medicine and Dentistry 15 50%
Biochemistry, Genetics and Molecular Biology 1 3%
Agricultural and Biological Sciences 1 3%
Nursing and Health Professions 1 3%
Psychology 1 3%
Other 1 3%
Unknown 10 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2014.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from Journal of Translational Medicine
#3,881
of 4,635 outputs
Outputs of similar age
#281,383
of 320,960 outputs
Outputs of similar age from Journal of Translational Medicine
#47
of 77 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,635 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,960 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.